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Abstract MAGE-C1/CT7, NY-ESO-1, GAGE and MAGE-
A4 are members of the cancer/testis (CT) antigen family, which
have been proposed as potential targets for cancer immunother-
apy. To determine the prevalence and biologic relevance of the
novel CT antigen MAGE-C1/CT7 and other antigens, 36 ovar-
ian borderline tumours (BTs), 230 primary ovarian carcinomas
(OCs) and 80 recurrent OCs were immunohistochemically
analysed using the monoclonal antibodies CT7-33 (MAGE-
C1/CT7), E978 (NY-ESO-1), clone 26 (GAGE) and 57B
(MAGE-A4). Positivity of at least one CT antigen was present
in 39.5 % (81/205) of primary OC and in 50 % (26/52) of all
recurrences. Expression of the novel CT antigen MAGE-
C1/CT7 was most commonly seen with positivity in 24.5 %
of primary and 35.1 % of recurrent OC. MAGE-A4, GAGE
and NY-ESO-1 expressions were seen in 22.7, 13.9 and 7.1 %
of primary and 22.6, 17.5 and 8.9 % of recurrent OC, respec-
tively. Analysis of histological subtypes (serous, endometrioid,
clear cell, mucinous and transitional) exhibited variable
expression with negativity in all mucinous OC. High-grade
serous OC revealed CTantigen expression in 5.6 to 28%with
MAGE-C1/CT7 being the most frequent, but without corre-
lation with stage or overall survival. MAGE-C1/CT7 expres-
sion and coexpression of CT antigens were significantly
correlated with grade of endometrioid OC. None of the
BT showed CT antigen expression. No significant correlation
was seen with stage, overall survival or response to chemo-
therapy. In summary, CT antigens are expressed in a certain
subset of OC with no expression in BT or OC of mucinous
histology. These findings may have implications for the
design of polyvalent vaccination strategies for ovarian
carcinomas.
Keywords NY-ESO-1 . MAGE-C1 . GAGE . CT7 .
Ovarian tumour . Cancer/testis antigens
A.-K. Zimmermann (*) :H. Moch :R. Caduff
Institute of Surgical Pathology, University Hospital Zurich,
Schmelzbergstrasse 12,
8091 Zurich, Switzerland
e-mail: Anne-Katrin.Zimmermann@usz.ch
J. Imig
Institute of Pharmaceutical Science, ETH Zurich,
Wolfgang-Pauli-Str. 10,
8093 Zurich, Switzerland
A. Klar
Tissue Biology Research Unit, Department of Surgery, University
Children’s Hospital, August-Forel-Str. 7,
8032 Zurich, Switzerland
C. Renner
Onkozentrum Hirslanden Zürich, Klinik Hirslanden,
Witellikerstrasse 40,
Zurich 8032, Switzerland
D. Korol
Institute of Social and Preventive Medicine, University of Zurich,
Vogelsangstrasse 10,
8091 Zurich, Switzerland
D. Fink
Department of Gynecology, University Hospital Zurich,
Frauenklinikstrasse 10,
8091 Zurich, Switzerland
S. Stadlmann :G. Singer
Institute of Pathology, Kantonsspital Baden AG,
5404 Baden, AG, Switzerland
A. Knuth
Clinic of Oncology, University Hospital Zurich, Rämistrasse 100,
8091 Zurich, Switzerland
Virchows Arch (2013) 462:565–574
DOI 10.1007/s00428-013-1395-3
Introduction
At the time of initial diagnosis, more than half of thewomenwith
ovarian carcinomas (OCs) present with an advanced stage
(FIGO stage III and IV). Treatment options include debulking
surgery with maximal reduction of the tumour mass. In addition,
platinum-based drugs and taxanes are used for systemic cyto-
toxic therapy. However, prognosis is still poor with 5-year
survival rates of only 18–47 % for advanced stages [1]. Since
the beginning of the 1990s, a standstill of treatment results is
seen that can hopefully be overcome by new treatment strategies.
Immunotherapy using cancer vaccines may represent a novel
approach to ameliorate outcome in women with ovarian carci-
nomas [2, 3]. Cancer/testis (CT) antigens are attractive targets
for immunotherapy as they display a restricted expression pat-
tern with occurrence in germ cells and a variety of malignant
tumours but not in normal tissues. So far, more than 100 CT
genes have been identified, which belong to at least 44 distinct
gene families. Most CT antigens correspond to chromosome X-
linked genes, but their function is largely unknown [4, 5]. Some
studies reported association of CT antigen expression with pro-
gression of cancer growth, dedifferentiation and/or poorer sur-
vival rates [6–10]. Furthermore, CTantigens or peptides derived
from CT antigens are candidates for cancer vaccination due to
their high immunogenicity. CT antigens have already been
evaluated as target antigens in clinical trials in patients with
advanced carcinomas and melanomas [4, 11–15]. Effective
application of immunotherapy depends on the prevalence and
intratumoural expression heterogeneity of CT antigens [16].
Ovarian cancer belongs to the group of cancers with
frequent expression of CT antigens. Members of the
MAGE family [17–19], GAGE [18, 20], BAGE [18],
XAGE [21], OY-TES-1 [22], SP17 [23], SCP-1 [24, 25],
SSX [26], NY-ESO-1 [27–29], AKAP and LAGE [28] have
been demonstrated at the RNA/DNA level. Accordingly,
immunotherapy could be an option for the treatment of
ovarian cancer after failure of first- and second-line thera-
pies [3, 30, 31]. However, only a limited number of ovarian
cancers respond to such therapies yet [30]. Some studies
using antibodies against GAGE [32], NY-ESO-1 [28, 29,
33], MAGE-A1 and -A4 [29, 32, 34, 35], SCP-1 [24], SP17
[23] and OY-TES-1 [22] have analysed the CT antigen
expression in OC at the protein level with divergent results.
MAGE-C1 was previously identified as a novel CT anti-
gen. The MAGE-C1/CT-7 gene has significant homology
with the MAGE-C2/CT-10 gene, and both genes map in close
proximity to chromosome Xq27 [36]. The CT7-33 monoclo-
nal antibody recognises MAGE-C1/CT7 in formalin-fixed,
paraffin-embedded tissues. Only nine OCs were recently stud-
ied using the MAGE-C1/CT7 antibody [37].
Expression of MAGE-C1/CT7, GAGE, NY-ESO-1 and
MAGE-A4 was determined by immunohistochemistry in a
large number of ovarian neoplasms. CT antigen expression
was correlated with clinico-pathological parameters and patient
outcome. Subgroup analysis of serous and endometrioid OC,
the most common histological subtype, was conducted. Our
data show CT antigen expression in 40–50 % of primary and
recurrent OC with surprisingly low expression of NY-ESO-1.
Material and methods
Patients
One hundred fifty consecutive primary OC specimens and 36
borderline tumours (BTs) were retrieved from the archives of the
Institute for Surgical Pathology, University Hospital Zurich,
Switzerland, covering the period from 1995 to 2005. Tissue
samples were fixed in 4 % neutral buffered formaldehyde,
embedded in paraffin and then used to construct one tissue
micro array (TMA)with cores of 150OCs, 36 BTs and 6 normal
tissue samples of the fallopian tube, as described previously
[38]. Routine haematoxylin and eosin sections were used for
histopathological evaluation. All tumours were reviewed by one
gynaecologic pathologist (RC). The tumour stage was assessed
according to the International Federation of Gynecology and
Obstetrics (FIGO) staging system. The tumour grade and histo-
logical subtype were defined according to the 2003 WHO
classification. Additionally to the Silverberg grading proposed
by WHO 2003 [39], serous carcinomas were graded according
to the two-tiered MD Anderson system [40]. Clinical and path-
ological characteristics were taken from clinical database and
pathology records. The median age at carcinoma diagnosis was
61years (range 20–87years), and overall survivalwas 2.25 years
(range 0–128 months). A detailed overview of the clinico-
pathological characteristics of carcinomas of this cohort from
Zurich is given in Table 1. Ovarian BT included 20 serous, 14
mucinous, 1 endometrioid BT, and 1 BTwith Brenner histology.
Median age at diagnosis of BT was 60.5 years (range 30–
85 years), and median survival was 6.2 years (range 4–
125 months).
A second patient cohort with paired tissue samples from
80 patients with advanced (FIGO II and III) high-grade (MD
Anderson grading) primary serous ovarian carcinomas and
their corresponding recurrences after chemotherapy was
available and was used to construct a second TMA. This
TMA consisted of formalin-fixed, paraffin-embedded tu-
mour tissue of OC from the Institutes of Pathology from
the University Hospital Bale, Cantonal Hospital St. Gallen,
Cantonal Hospital Baden and Cantonal Hospital Liestal,
diagnosed and treated between 1985 and 2003. Median
age at diagnosis of OC was 59 years (range 20–77 years),
and median recurrence-free survival (RFS) was 9 months
(range 1–85 months). Recurrence was defined as an eleva-
tion of CA-125 levels with tumour confirmation by radio-
logical examination and/or during secondary surgical
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procedures. Chemoresistance was defined as OC recurrence
within 6 months after finishing chemotherapy. Clinico-
pathological details of this cohort have been recently
reported [41, 42] and are shown in Table 2.
The complete tumour cohort included 230 primary OCs,
80 recurrent high-grade serous OCs and 36 ovarian BTs.
The project was approved by the local ethics review boards
of Bale and Zurich (Kantonale Ethikkomission Zurich, StV
27–2009).
Histology and immunohistochemistry
Three-micrometre-thick sections of TMA blocks and formalin-
fixed, paraffin-embedded tissues were mounted on glass slides
(Super-Frost Plus, Menzel, Braunschweig, Germany),
deparaffinised, rehydrated and stained with haematoxylin–eosin
using standard histological techniques. For immunohistochemi-
cal staining of TMA and large sections, the Ventana Benchmark
automated staining system (Ventana Medical Systems,
Tucson, AZ, USA) and Ventana reagents were used. After
deparaffinisation in xylene, the slides were rehydrated in decreas-
ing concentrations of ethanol. Endogenous peroxidase was
blocked using the Ventana endogenous peroxidase blocking kit
after a rinse with distilled water. For antigen retrieval, the slides
were heated with cell conditioning solution (CC1, Ventana)
according to the manufacturer’s instructions. For the detection
of the MAGE-A4 protein, the 57B monoclonal antibody (1:50,
kindly provided by Dr. G.C. Spagnoli, University of Basel,
Switzerland) was used, which recognises most of the MAGE-
A family members, but predominantly the MAGE-A4 protein.
Primary antibodies against MAGE-C1/CT-7 (clone CT7-33,
Table 1 Clinico-pathological characteristics of primary ovarian carcinomas of the Zurich cohort
Histology Serous, n=68 (%) Clear cell, n=24 (%) Endometrioid, n=31 (%) Mucinous, n=16 (%) Othersa, n=11 (%)
Three-tiered grading systemb
G1 6 (9) n.d. 7 (22) n.d. n.d.
G2 32 (47) n.d. 15 (48) n.d. n.d.
G3 30 (44) n.d. 9 (29) n.d. n.d.
Two-tiered grading systemc
Low grade 6 (9) n.d. n.d. n.d. n.d.
High grade 62 (91) n.d. n.d. n.d. n.d.
FIGO stage
I 6 (9) 3 (13) 12 (44) 12 (75) 1 (11)
II 4 (6) 2 (9) 4 (15) 0 (0) 2 (22)
III 29 (43) 13 (56) 6 (22) 3 (19) 5 (56)
IV 28 (42) 5 (22) 5 (19) 1 (6) 1 (11)
Localised vs. advanced FIGO stage
Localised stage (FIGO I) 6 (9) 3 (13) 12 (44) 12 (75) 1 (11)
Advanced stage (FIGO II–IV) 61 (91) 20 (87) 15 (56) 4 (25) 8 (89)
Residual tumour status
R0 (no residual tumour) 12 (24) 4 (25) 9 (47) 4 (36) 2 (22)
R1 (residual tumour <2 cm) 18 (36) 4 (25) 4 (21) 5 (46) 1 (11)
R2 (residual tumour >2 cm) 20 (40) 8 (50) 6 (32) 2 (18) 6 (67)
n.d. not done
a Nine transitional and one anaplastic carcinoma and one malignant Mullerian mixed tumour
b Three-tiered grading system according to WHO 2003 only for serous carcinomas (Silverberg grading) and endometrioid carcinomas
c Two-tiered MD Anderson grading only for serous carcinomas
Table 2 Clinico-pathological characteristics of ovarian carcinomas of
the Bale cohort
High-grade advanced serous ovarian carcinomasa n=80 (%)
Residual tumour status
R0 (no residual tumour) 32 (42)
R1 (residual tumour <2 cm) 23 (30)
R2 (residual tumour >2 cm) 22 (28)
Response to chemotherapyb
Sensitive 57 (72)
Resistant 22 (28)
a Grading was performed according to the MD Anderson grading
system. All carcinomas were of advanced FIGO stage (FIGO≥II)
b Chemosensitivity was defined as RFS>6 months after chemotherapy;
chemoresistance was defined as RFS<6 months after chemotherapy
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1:80, Dako, Barr, Switzerland), GAGE (clone 26, reacts with
GAGE-3, -4, -5, -6 and -7B proteins; 1:2,000; BD Transduction
Laboratories, San Jose, CA, USA) and NY-ESO-1 (clone E978,
1:50, ZymedLaboratories, South San Francisco, CA,USA)were
applied adjusted to the Ventana Benchmark system after
performing titrations. iVIEW-DAB was used as chromogen.
Immunoreactivity was cytoplasmic for MAGE-A4,
MAGE-C1/CT-7 and GAGE and both nuclear and cytoplas-
mic for NY-ESO-1. CT antigen expression was scored
according to the percentage of positive cells as negative
(0 %), focal (1–25 %), moderate (26–50 %), and diffuse
(>50 % positive cells). Testicular tissue served as a positive
control. Homogenous staining was defined as positivity in
more than 50 % of tumour cells.
Normal fallopian tubal epithelium and ovarian stroma tissue
were consistently negative for MAGE-A4, MAGE-C1/CT7
(see Fig. 1) and GAGE. Diffuse weak staining of NY-ESO-1
was initially observed in the epithelium of the fallopian tube.
Fig. 1 CT antigen expression
in ovarian neoplasms. Strong
and homogeneous staining of
NY-ESO-1 (a), GAGE (b),
MAGE-A4 (c) and MAGE-C1/
CT7 (d) was observed in
ovarian carcinomas. Borderline
tumours (e) and epithelium of
the fallopian tube (f) did not
exhibit expression of MAGE-
C1/CT7 (shown) or other CT
antigens
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By RT-PCR analyses, low amounts of NY-ESO-1 mRNA
could be identified in tissue of the fallopian tube, but NY-
ESO-1 protein was absent in Western blot analyses (see
Fig. 2). In Western blot, strong bands of NY-ESO-1 protein
were seen in immunohistochemically positive OC and the three
controls, whereas immunohistochemically negative OC and
BT did not demonstrate NY-ESO-1 protein in Western blot
analysis. Consequently, NY-ESO-1 antibody was diluted to
the point where tubal epithelium was negative (1:50).
Statistical analysis
Statistical analyses were performed using SPSS version 20
software. Associations between categorical groups (i.e. CT
antigen expression and clinico-pathological parameters) were
tested using the Pearson χ2 test or Fisher’s exact test. Survival
analysis was performed on 150 OCs of different histology. For
univariate analysis, Kaplan–Meier analysis survival curves
were constructed using the product limit method. The logrank
test was applied to assess the statistical significance of the
association between variables and patient survival. Two-tailed
p≤0.05 was considered to be significant.
Results
CT antigen expression in primary ovarian neoplasms
CT antigen expression was analysed in TMA tumour tissue
cores of 230 primary OCs and 36 ovarian BTs. Evaluation of
the markers was not always possible in all tumour samples due
to loss of tissue cores related to the TMA technology. In
primary OC, MAGE-C1/CT7 was seen most frequently (24.
5 %, 52/212), followed by MAGE-A4 (22.7 %, 49/216),
GAGE (13.9 %, 30/216) and NY-ESO-1 (7.1 %, 15/211).
Examples of CT antigen staining are shown in Fig. 1.
Expression differed among histological subtypes of OC,
though without significant correlation. Whereas all mucinous
carcinomas were CT antigen negative (0/15), other histologi-
cal subtypes (serous, clear cell, endometrioid and transitional)
exhibited variable CT antigen expression between 4 to 30 %
(an overview from the Zurich cohort is given in Table 3). In
serous carcinomas of both cohorts, MAGE-C1/CT7 was most
frequently expressed (36/131, 27.5 %), followed by MAGE-
A4 (35/135, 25.9%), GAGE (18/135, 13.3%) and NY-ESO-1
(8/130, 6.2 %); see Table 4.
Tissue cores of OC exhibited heterogenous staining
(<50 % of tumour cells stained) of MAGE-A4, NY-ESO-
1, MAGE-C1/CT7 and GAGE in 55.1, 33.3, 80.8 and 53.
3 %, respectively. To better evaluate the prevalence of CT
antigen expression, large sections of 20 OCs with negativity
for NY-ESO-1 in the TMA cores were additionally
immunohistochemically analysed. One tumour with diffuse
NY-ESO-1 positivity, three tumours with focal NY-ESO-1
positivity, four tumours with focal GAGE, three tumours
with focal MAGE-C1/CT7 and two tumours with diffuse
MAGE-A4 positivity were additionally identified. BTs were
negative for all CT antigens analysed (example of negative
MAGE-C1/CT7 staining is shown in Fig. 1e).
CT antigen expression and clinico-pathological parameters
FIGO stage was significantly associated with survival (p=0.
006), but there was no significant correlation between CT
antigen expression and FIGO stage or survival. Comparison
of clinico-pathological variables with CT antigen expression
in the Zurich cohort is summarised in Table 3. A separate
subgroup analysis of serous carcinomas from the combined
Zurich and Bale cohort (see Table 4) was conducted but did
not reveal significant association with grade (MD Anderson
grading) or FIGO stage (localised vs. advanced). Also, there
was no significant association with response to chemother-
apy. Though higher frequencies of MAGE-C1/CT7 and
GAGE expression were seen in recurrent serous carcinomas
(20/57 (35.1 %) and 10/57 (17.5 %)) compared to tissue
from primary manifestation (16/64 (25 %) and 5/67
(7.5 %)), this was not significant. In recurrent OC,
MAGE-C1/CT7 (35.1 %, 20/57) was most frequent,
followed by MAGE-A4 (22.6 %, 14/62), GAGE (17.5 %,
10/57) and NY-ESO-1 (8.9 %, 5/56). MAGE-C1/CT7 ex-
pression was significantly associated with grade in the sub-
group of endometrioid carcinomas (p=0.04).
Fig. 2 Western blot analysis with anti-NY-ESO-1 antibody E978 on
tumour and non-tumour tissues. Ovarian carcinoma with positivity for
NY-ESO-1 in immunohistochemistry (column 1), NY-ESO-1
immunohistochemically negative ovarian carcinoma (column 2),
fallopian tube (column 4) and borderline tumours (columns 5 and 6).
Negative control: myocardial tissue (column 3). Positive controls: mela-
noma cell line SK-MEL-37 (column 7), multiple myeloma cell line U266
(column 8) and bacterial recombinant NY-ESO-1 protein (column 9)
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Coexpression of CT antigens
At least one of the four examined CT antigens was
expressed in 39.5 % (81/205) of all primary and 50 %
(26/52) of recurrent ovarian carcinomas. Two or more
CT antigens were expressed in 10.7 % (22/205) of
primary OC and 11.5 % (6/52) of recurrent OC. The
pattern of coexpression from cases where all four tested
CT antigens could be evaluated is visualised in a Venn
diagram (see Fig. 3). Interestingly, only one tumour
sample showed isolated expression of NY-ESO-1,
whereas most NY-ESO-1 positive cases (11/12, 92 %)
revealed coexpression of MAGE-A4, MAGE-C1/CT7
and/or GAGE. Coexpression of CT antigens was signif-
icantly associated with histological subtype (p=0.02);
see Table 5. Presence of CT antigen coexpression was
not associated with overall survival.
The subgroup analysis for all serous carcinomas revealed
no significant correlation of CT antigen coexpression and
grade (MDAnderson), FIGO stage, response to chemotherapy
or recurrence. In the subgroup of endometrioid carcinomas,
coexpression was significantly associated with grade
(p=0.03).
Discussion
We demonstrate protein expression data of MAGE-C1, MAGE-
A4, NY-ESO-1 and GAGE in ovarian BT as well as in primary
and recurrent OC. Whereas none of the borderline tumours
showed expression of CTA, positive immunohistochemistry
was seen in about 40 to 50 % of primary and recurrent OC.
This finding is of clinical significance since previous studies have
shown that CT antigens are able to induce specific immune
responses. Antibodies directed against MAGE and other CT
antigens were detected in the serum of (ovarian) cancer patients
[2, 43–45], suggesting that these antigens are targets for peptide
vaccination in patients with advanced ovarian cancer.
Table 3 CT antigen expression in primary ovarian carcinomas (Zurich cohort) according to clinico-pathological characteristics
NY-ESO-1 MAGE-A4 MAGE-C1/CT7 GAGE
n (%) p valuea n (%) p valuea n (%) p valuea n (%) p valuea
Histological subtype of primary OC
Serous 3/68 (4.4) n.s. 17/68 (25) n.s. 20/67 (30) n.s. 13/68 (19.1) n.s.
Clear cell 2/24 (8.3) 7/24 (29.2) 7/24 (29.2) 6/24 (25)
Endometrioid 2/31 (6.5) 4/31 (12.9) 8/31 (25.8) 3/31 (9.7)
Mucinous 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0)
Othersb 3/11 (27.3) 3/11 (27.3) 1/11 (9.1) 3/11 (27.3)
FIGO stage
I 1/34 (2.9) n.s. 3/34 (8.8) n.s. 5/34 (14.7) n.s. 2/34 (5.9) n.s.
II 1/12 (8.3) 1/12 (8.3) 2/12 (16.7) 2/12 (16.7)
III 3/55 (5.5) 12/55 (21.8) 14/55 (25.5) 11/55 (20)
IV 5/40 (12.5) 13/40 (32.5) 13/39 (33.3) 8/40 (20)
n.s. not significant
a p value, Fisher’s exact test (two sided)
b Other histological subtypes comprise nine transitional carcinomas, one anaplastic carcinoma and one malignant Mullerian mixed tumour. Only
transitional carcinomas showed positivity for CT antigens
Table 4 Subgroup analysis of
CT antigen expression in prima-
ry serous ovarian carcinomas
Zurich and Bale cohort com-
bined, n=148
NY-ESO-1 MAGE-A4 MAGE-C1/CT7 GAGE
n (%) n (%) n (%) n (%)
Positive cases 8/130 (6.2) 35/135 (25.9) 36/131 (27.5) 18/135 (13.3)
MD Anderson grading
Low grade 1/6 (16.7) 1/6 (16.7) 1/6 (16.7) 1/6 (16.7)
High grade 7/124 (5.6) 34/129 (26.4) 35/125 (28) 17/129 (13.2)
Localised vs. advanced FIGO stage
Localised stage (FIGO I) 0/6 (0) 0/6 (0) 2/6 (33.3) 0/6 (0)
Advanced stage (FIGO II–IV) 8/123 (6.5) 35/128 (27.3) 34/124 (27.3) 18/128 (14)
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The new CT antigen MAGE-C1/CT7 was the most fre-
quent CT antigen in primary OCs (24.5 %, 52/212) and
recurrent carcinomas (35.1 %, 20/57). Whereas no association
was seen with FIGO stage, overall survival or response to
chemotherapy, in the subgroup of endometrioid carcinomas,
MAGE-C1/CT7 expression correlated significantly with
grade. In ovarian neoplasms, MAGE-C1/CT7 has primarily
been analysed at the level of gene transcription, but protein
expression has not yet been studied to a larger extent. One
small MAGE-C1/CT7 protein expression study reported
immuno-positivity in six of nine (66 %) OCs [37]. Humoral
and cellular immunoresponses were demonstrated in multiple
myeloma patients [44, 46], suggesting that MAGE-C1/CT7
could be a potential target for vaccination strategies.
GAGE protein was recently not identified in OC, but
only ten OC cases were studied [32]. GAGE mRNA expres-
sion was reported in 10 and 26.8 % of ovarian neoplasms
[17, 47]. This GAGE mRNA expression is consistent with
our data on protein level, with expression rate of 13.9 %
(30/216). Our MAGE-A4 data with expression in 22.7 %
(49/212) of primary OC are consistent with two previous
studies, reporting MAGE-A4 immunoreactivity in 13.9 %
(17/122) and 11 % (13/117) [34, 35]. In contrast, Yakirevich
et al. identified MAGE-A4 positivity in 57 % (30/53) of
serous OC [29], using large sections and less diluted anti-
bodies (1:20).
NY-ESO-1 as one of the best characterised CT antigens
was recently ranked by an NCI panel as among the top ten
antigens for the development of human cancer vaccines
[48]. Therefore, the prevalence of NY-ESO-1-positive OC
is of high clinical relevance. We identified NY-ESO-1 pro-
tein expression in 7.1 % of primary OC (15/211) and 8.9 %
of recurrent OC (5/56). This was unexpectedly low com-
pared to previously published studies with expression rates
of 18.8 % (10/53) [29] and 43 % (62/142) [28]. In contrast,
Gjerstorff et al. were not able to detect NY-ESO-1 protein at
all in ten OC cases [32]. Several parameters can influence
immunohistochemical results.
Three different antibodies (D8.38, E978 and ES121) with
different specificity were used in previous studies. D8.38 is
reactive with NY-ESO-1 as well as LAGE1, a CT antigen
with 94 % homology to NY-ESO-1. Initial publication of
E978 and ES121 antibodies described similar specific im-
munohistochemical staining patterns [49], though ES121
was generated against a shorter NY-ESO-1 recombinant
protein than E978 and is thus possibly less specific. One
would expect that the highest results were detected with
antibody D8.38. This was not the case; 18.9 % (10/53) of
ovarian carcinomas were positive with antibody D8.38 [29],
less than half than with antibody ES121 [28], where 43 %
Fig. 3 Venn diagram with coexpression of CT antigens. The numbers
indicate the absolute amount of positive cases. Numbers in the small
circles indicate the NY-ESO-1-positive tissue samples
Table 5 Coexpression of can-
cer/testis antigens according to
clinico-pathological parameters
(Zurich cohort)
n.s. not significant
aPearson χ2 test (two sided)
bOther histological subtypes
comprise nine transitional carci-
nomas, one anaplastic carcinoma
and one malignant Mullerian
mixed tumour. Only transitional
carcinomas showed expression
of CT antigens
One CT antigen Two CT antigens More than two CT antigens p value
n (%) n (%) n (%)
Histological subtype of primary OC
Serous 1/67 (24) 9/67 (13.4) 5/67 (13.4) 0.02a
Clear cell 3/24 (12.5) 3/24 (12.5) 4/24 (16.7)
Endometrioid 5/31 (16.1) 0/31 (0) 4/31 (12.9)
Mucinous 0/15 (0) 0/15 (0) 0/15 (0)
Othersb 0/11 (0) 0/11 (11.1) 3/11 (27.3)
FIGO stage
1 3/34 (8.8) 1/34 (2.9) 2/34 (5.9) n.s.
2 1/12 (8.3) 1./12 (8.3) 1/12 (8.3)
3 13/55 (23.6) 5/55 (9.1) 5/55 (9.1)
4 7/39 (4.5) 5/39 (12.8) 6/39 (15.4)
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(62/142) of OC were positive. Another study that used the
same antibody as we did (E978) did not detect protein
expression in OC at all (0/10 [32]).
CT antigens are known for their restricted expression pat-
tern in germs cells and malignant tumours and no expression
in normal tissue. Initially, diffuse weak staining of NY-ESO-1
was observed in fallopian tubal epithelium, all BTand 44% of
OC. In our analysis, we performed extensive positive and
negative control studies. In Western blot analyses, NY-ESO-
1 protein could not be detected in tubal epithelium, BT and
immunohistochemically negative OC, whereas it was clearly
present in immunohistochemically positive tumours and pos-
itive controls. Consequently, we applied for immunohisto-
chemistry a NY-ESO-1 antibody dilution resulting in
negativity of tubal epithelium (1:50).
Intratumoural heterogeneity of CT antigen expression has
been reported and is a particular problem in tissue microarray
approaches. Lack of expression in a substantial number of cancer
cells in CT antigen-positive tumours has decisive implications
for the development of CT antigen-targeted ovarian cancer ther-
apies because only a subset of cancer cells are potentially affect-
ed by a tumour vaccination approach. Therefore,
immunohistochemical evaluation of CT antigen distribution is
important in the response evaluation of CT antigen-targeted
therapy. Heterogenous staining (<50 % of tumour cells) of the
CT antigens MAGE-A4, NY-ESO-1, MAGE-C1/CT7 and
GAGE was the predominant pattern in most OC tissue cores
on the TMA. Our large section analysis with the monoclonal
NY-ESO-1-specific antibody E978 [49–51] revealed that we
missed in the TMA analysis 4 of 20 (20 %) tumours with NY-
ESO-1 positivity due to intratumoural expression heterogeneity.
Further, four, three and two tumours with GAGE (20 %),
MAGE-C1/CT7 (15%) andMAGE-A4 (10%) expression were
identified in large sections, which were initially missed on the
TMA analysis. Yakirevich et al. have also reported intratumoural
expression heterogeneity forMAGE-A4 andNY-ESO-1. In their
study, NY-ESO-1was focally (<25% positive cells) seen in 9%,
moderately (<50 % positive cells) in 4 % and diffusely (>50 %
positive cells) in 6 % of serous ovarian cancers [29]. Therefore,
the TMA approach underestimates the prevalence of NY-ESO-1
protein and other CT antigens.
CT antigens were not expressed in BT, confirming previous
MAGE-A4 data by Yakirevich et al. [29]. Coexpression of
different CTantigens (two or more CTantigens) was more often
seen in recurrent serous OC (50 %) compared to primary serous
OC (39.5 %) though this was not significant. Coexpression was
significantly associated with tumour differentiation grade
of endometrioid carcinomas. Information on CT antigen
coexpression is crucial for the design of polyvalent vaccine
strategies because OC patients can be selected for combined or
sequential vaccination with two or more tumour antigens. Such
strategies have the potential of reducing or even preventing the in
vivo selection of tumour cell variants with antigen loss.
Subgroup analysis of serous OC, representing the most
common histological subtype of OC, was conducted for
several clinico-pathological parameters but did not reveal a
significant correlation. Interestingly, mucinous OC was neg-
ative for all CT antigens. This result was congruent with
previous reports [28, 34] and is consistent with the hypoth-
esis that mucinous OC has a different histogenesis and
biologic behaviour [52]. The few transitional OC that were
included in our study cohort showed a surprisingly high (co)
expression rate of the examined CT antigens.
In summary, our data provide evidence that a subset of
primary and recurrent OC do express the examined CT
antigens MAGE-A4, NY-ESO-1, MAGE-C1/CT7 and
GAGE, and these tumours are potentially attackable with
immunotherapies. In our cohort, the new CT antigen
MAGE-C1/CT7 is the most frequently expressed antigen
and thus seems to be interesting for further investigation.
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